In situ photoimmunotherapy for cutaneous granuloma caused by itraconazole‐resistant Candida guilliermondii. Issue 5 (21st June 2016)

• Record Type: Journal Article
• Authors: Shi, Lei; Luo, Min; Chen, Wei R.; Hu, Chan; Zhang, Guolong; Zhang, Fuhe; Chen, Jia; Mo, Xiaohui; Cai, Qing; Yang, Lianjuan; Wang, Xiuli
• Is Part Of: Dermatologic therapy. Volume 29:Issue 5(2016)
• Page Start: 353
• Page End: 357
• Publication Date: 2016-06-21
• Subjects: Candida guilliermondii -- cutaneous granuloma -- in situ photoimmunotherapy -- photothermal therapy; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.12376
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: Cutaneous granulomas caused by Candida guilliermondii are difficult to cure. In situ photoimmunotherapy (ISPI) is a novel method composed of local photothermal therapy and immunoadjuvant. In this study, ISPI was used the first time clinically for cutaneous granuloma caused by itraconazole‐resistant C.guilliermondii. A 10‐week cycle of ISPI was composed of (1) 5% imiquimod applied topically every other day and (2) irradiation of lesions with an 808‐nm diode laser at Days 14, 28, 42, and 56. Here we report our first case. A patient was treated with ISPI for four cycles. After the treatment, the lesions were eliminated without recurrence during a 12‐month follow‐up. Our results demonstrate that ISPI can be used as an effective treatment modality for cutaneous fungal granuloma.